ClinicalTrials.gg
Sign In
RecruitingNCT06237452RESTORATiVE303Updated Nov 9, 2026

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

A Phase 3 interventional study of VE303 and Placebo in Clostridium Difficile, Clostridium Difficile Infections and Clostridium Difficile Infection Recurrence, sponsored by Vedanta Biosciences, Inc.. Recruiting at 215 sites in 24 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Vedanta Biosciences, Inc. · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Updated Nov 9, 2026Site recruiting status changedStudy contact changed+2 moreGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
852
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

02

Conditions studied

  • Clostridium Difficile
  • Clostridium Difficile Infections
  • Clostridium Difficile Infection Recurrence
  • Clostridioides Difficile Infection
  • Clostridioides Difficile Infection Recurrence
  • CDI
  • C. Diff Infection
  • Recurrent Clostridium Difficile Infection
  • C.Difficile Diarrhea
  • Diarrhea Infectious
03

In context

Clostridium Infections

251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.

This study's planned enrollment of 852 is above the median of 64 across 185 interventional studies indexed under Clostridium Infections.

Browse Clostridium Infections studies →

Lead sponsor

Vedanta Biosciences, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria (For enrollment in Stage 1: recurrent CDI population):

  • Age ≥ 12 years where permitted, and ≥ 18 years in other locations, with a laboratory-confirmed qualifying episode of CDI and at least 1 prior occurrence within the last 6 months

Key Inclusion Criteria (For enrollment in Stage 2: primary CDI with high-risk for recurrence population):

  • Age ≥ 75 years with a laboratory-confirmed qualifying episode of CDI

  • OR age ≥ 12 years where permitted, and ≥ 18 years in other locations, with least two of the following risk factors:

    1. Age ≥ 65 years
    2. Kidney dysfunction, defined as estimated \< 60 mL/min/1.73 m\^2 at the time of the qualifying CDI episode
    3. History of regular use of a proton pump inhibitor (PPI) within the past 2 months and expectation of continued use of PPIs throughout the study
    4. History of a prior CDI episode between 6 and 12 months prior to enrollment
    5. due to an underlying disease or its treatment
    6. Has undergone solid organ or hematopoietic stem cell transplantation

Key Inclusion Criteria (For enrollment in Stage 1 or 2):

  • The qualifying episode of CDI must meet all the following criteria:

    1. New onset of ≥ 3 unformed bowel movements (ie, Types 5 to 7 on the Bristol stool scale) within 24 hours for 2 consecutive days
    2. CDI symptoms started within 4 weeks prior to initiation of standard of care (SoC) antibiotic therapy for CDI
    3. Stool sample collected before (or no later than 72 hours after) initiation of SoC antibiotic therapy that was positive in a CDI laboratory test, defined as enzyme immunoassay (EIA) for toxin A/B and glutamate dehydrogenase (GDH) with polymerase chain reaction (PCR) reflex testing for discordant EIA/GDH results, performed at either a local laboratory or the central laboratory
    4. Diarrhea considered unlikely to have another etiology

  • Prior to receiving any study medication, the participant should:

    1. Receive and complete a course of SoC antibiotic therapy for at least 10 days, up to a maximum of 28 days (Note: choice of agent is at the physician's discretion and antibiotic tapering is not allowed). It is permissible for decentralized participants to be randomized during SoC antibiotic administration.
    2. Meet the criterion of a successful clinical response, defined attaining symptomatic control of the qualifying CDI episode, ie, \< 3 loose/unformed bowel movements per 24 hours for at least 2 consecutive days
  • Able to receive the first dose of study drug on the last planned day of SoC antibiotic administration for a qualifying CDI episode, or no later than 2 days after completion of antibiotic dosing
  • Recovered from any complications of severe or fulminant CDI and be clinically stable by the time of randomization

Key Exclusion Criteria (For both Stage 1 and Stage 2):

  • History of chronic diarrhea (defined as ≥ 3 loose stools per day lasting for at least 4 weeks) within 3 months prior to randomization that is not related to CDI
  • Known or suspected toxic megacolon or small bowel ileus at the time of randomization
  • History of confirmed celiac disease, inflammatory bowel disease, microscopic colitis, short gut, GI tract fistulas, or a recent episode (within 6 months of screening) of intestinal ischemia or ischemic colitis
  • Receipt of bezlotoxumab during the course of SoC antibiotic treatment for the qualifying CDI episode
  • Use of antidiarrheal drugs (eg, loperamide, diphenoxylate) within 3 days prior to the planned first dose of study drug
  • Anticipated administration of oral or parenteral antibacterial therapy for a non-CDI indication after randomization through Week 24 (end of study)
  • Probiotics, whether characterized as a dietary/food supplement, or a drug, are prohibited within 2 days before starting study drug and through the dosing period. (Note: consumption of food-based products such as yogurt, kombucha, and kefir are permitted.)
  • (ANC) of \< 0.5 ×10\^9 cells/L on 2 consecutive occasions within 7 days prior to randomization, or sustained ANC \< 1.0 × 10\^9 cells/L
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
852 participants (estimated)

Study arms

  • Experimental
    VE303

    Subjects assigned to the VE303 arm will take 3 capsules containing VE303 per day for 14 days after completing 10 to 21 days of standard of care antibiotic treatment for the qualifying CDI episode.

    Biological: VE303

  • Placebo comparator
    Placebo

    Subjects assigned to the placebo arm will take 3 placebo capsules per day for 14 days after completing 10 to 21 days of standard of care antibiotic treatment for the qualifying CDI episode.

    Biological: Placebo

Interventions

  • BiologicalVE303

    VE303 is a live biotherapeutic product (LBP) consisting of 8 clonally derived, nonpathogenic, nontoxigenic, commensal bacteria strains manufactured under Good Manufacturing Practices (GMP) conditions.

  • BiologicalPlacebo

    Placebo capsules contain microcrystalline cellulose. Placebo capsules are visually identical to and not discernible from VE303 capsules. Placebo capsules will not contain any VE303 drug product.

06

What researchers measure

Primary outcomes

  1. CDI Recurrence Rate at Week 8

    Proportion of participants with laboratory-confirmed CDI recurrence before or at Week 8.

    Time frame: 8 weeks

07

Study locations

130 of 215 sites recruiting

Showing the first 100 of 215 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

09

Updates

4 registry updates since Sep 25, 2026
Sites
2 sites added, 2 sites removed. 26 sites changed recruiting status (25 now active, not recruiting, 1 now withdrawn)
Show 26 sites
  • Hadassah Medical Centre · Jerusalem, IsraelActive, not recruiting→Withdrawn
  • New York Presbyterian Hospital · New York, United StatesRecruiting→Active, not recruiting
  • Medical University of South Carolina · Charleston, United StatesRecruiting→Active, not recruiting
  • Virginia Mason Medical Center · Seattle, United StatesRecruiting→Active, not recruiting
  • CCIH - Consultoria em Controle de Infecção Hospitalar Ltda · Belo Horizonte, BrazilRecruiting→Active, not recruiting
  • Fundacao Universidade de Caxias do Sul - Hospital Geral de Caxias do Sul · Caxias do Sul, BrazilRecruiting→Active, not recruiting
  • Associação Educadora São Carlos AESC - Hospital Mãe de Deus - Centro de Pesquisa · Porto Alegre, BrazilRecruiting→Active, not recruiting
  • Multiprofile Hospital for Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD · Gorna Oryahovitsa, BulgariaRecruiting→Active, not recruiting
  • Hospital St. Joseph · Les Paris, FranceRecruiting→Active, not recruiting
  • CHU Bordeaux - Hopital Saint Andre Service de medecine interne et maladies infectieuses · Bordeaux Cedex, FranceRecruiting→Active, not recruiting
  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Paris Ile-de-France Ouest - Raymond-Poincare · Garches, FranceRecruiting→Active, not recruiting
  • Komárom-Esztergom Vármegyei Szent Borbála Kórház · Tatabánya, HungaryRecruiting→Active, not recruiting
  • Semmelweis Egyetem · Budapest, HungaryRecruiting→Active, not recruiting
  • Rabin Medical Center - Beilinson Hospital · Petah Tikva, IsraelRecruiting→Active, not recruiting
  • Carmel Medical Center · Haifa, IsraelRecruiting→Active, not recruiting
  • Hillel Yaffe MC, Clinical Research Unit · Hadera, IsraelRecruiting→Active, not recruiting
  • Ospedale Fatebenefratelli e Oftalmico, ASST Fatebenefratelli Sacco · Milan, ItalyRecruiting→Active, not recruiting
  • Fondazione IRCCS San Gerardo dei Tintori · Monza, ItalyRecruiting→Active, not recruiting
  • Osp. Pediatrico Bambino Gesù, IRCCS · Roma, ItalyRecruiting→Active, not recruiting
  • Presidio Ospedaliero di Vittorio Veneto · Vittorio Veneto, ItalyRecruiting→Active, not recruiting
  • FAICIC S de RL de C.V. - Gastroenterology · Veracruz, MexicoRecruiting→Active, not recruiting
  • Spitalul Clinic de Boli Infectioase Cluj-Napoca · Cluj-Napoca, RomaniaRecruiting→Active, not recruiting
  • Yonsei University, Wonju Severance Christian Hospital · Wŏnju, South KoreaRecruiting→Active, not recruiting
  • Hospital Universitario Mutua de Terrassa · Terrassa, SpainRecruiting→Active, not recruiting
  • North Texas Infectious Disease Consultants, P.A. · Dallas, United StatesRecruiting→Active, not recruiting
  • GI Alliance · Cedar Park, United StatesRecruiting→Active, not recruiting
Show 2 added (2 Israel)
  • Shamir Medical Center (Assaf Harofeh) · Tsrifin, Israel
  • The Chaim Sheba Medical Center · Tel HaShomer, Israel
Show 2 removed
  • Shamir Medical Center (Assaf Harofeh) · Ẕerifin, Israel
  • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
across 4 updates, Sep 29, 2026 – Nov 9, 2026
Contact
Study contact changed: C•••@vedantabio.com · •••1427→C•••@vedantabio.com · •••1427. See the current contact
Oct 30, 2026
Site contacts
Changed at 25 sites. See the sites
Show 25 sites
  • New York Presbyterian Hospital · New York, United StatesContact removed t•••@med.cornell.edu · •••4463
  • Medical University of South Carolina · Charleston, United StatesContact removed h•••@musc.edu · •••4100
  • Virginia Mason Medical Center · Seattle, United StatesContact removed e•••@commonspirit.org · •••1416
  • CCIH - Consultoria em Controle de Infecção Hospitalar Ltda · Belo Horizonte, BrazilContact removed d•••@freirepesquisa.com.br · •••0085
  • Fundacao Universidade de Caxias do Sul - Hospital Geral de Caxias do Sul · Caxias do Sul, BrazilContact removed r•••@ucs.br · •••7200
  • Associação Educadora São Carlos AESC - Hospital Mãe de Deus - Centro de Pesquisa · Porto Alegre, BrazilContact removed g•••@coracentro.com.br · •••3930
  • Multiprofile Hospital for Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD · Gorna Oryahovitsa, BulgariaContact removed g•••@mcmedicaplus.com · •••6101
  • Hospital St. Joseph · Les Paris, FranceContact removed s•••@ghpsj.fr · •••6207
  • CHU Bordeaux - Hopital Saint Andre Service de medecine interne et maladies infectieuses · Bordeaux Cedex, FranceContact removed j•••@chu-bordeaux.fr · •••2433
  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Paris Ile-de-France Ouest - Raymond-Poincare · Garches, FranceContact removed c•••@aphp.fr · •••5655
  • Komárom-Esztergom Vármegyei Szent Borbála Kórház · Tatabánya, HungaryContact removed h•••@tatabanyakorhaz.hu · •••9431
  • Semmelweis Egyetem · Budapest, HungaryContact removed k•••@semmelweis.hu · •••2783
  • Rabin Medical Center - Beilinson Hospital · Petah Tikva, IsraelContact removed m•••@clalit.org.il · •••5417Contact removed V•••@clalit.org.il · •••3570
  • Carmel Medical Center · Haifa, IsraelContact removed m•••@clalit.org.il · •••8822
  • Hillel Yaffe MC, Clinical Research Unit · Hadera, IsraelContact removed j•••@hymc.gov.il · •••4929Contact removed l•••@hymc.gov.il · •••2396
  • Ospedale Fatebenefratelli e Oftalmico, ASST Fatebenefratelli Sacco · Milan, ItalyContact removed p•••@asst-fbf-sacco.it · •••2582
  • Fondazione IRCCS San Gerardo dei Tintori · Monza, ItalyContact removed s•••@gmail.com · •••9600
  • Osp. Pediatrico Bambino Gesù, IRCCS · Roma, ItalyContact removed g•••@opbg.net · •••2188
  • Presidio Ospedaliero di Vittorio Veneto · Vittorio Veneto, ItalyContact removed a•••@email.it · •••5337
  • FAICIC S de RL de C.V. - Gastroenterology · Veracruz, MexicoContact removed a•••@faicic.com.mx · •••9780
  • Spitalul Clinic de Boli Infectioase Cluj-Napoca · Cluj-Napoca, RomaniaContact removed a•••@yahoo.com · •••1470
  • Yonsei University, Wonju Severance Christian Hospital · Wŏnju, South KoreaContact removed h•••@hanmail.net · •••1209
  • Hospital Universitario Mutua de Terrassa · Terrassa, SpainContact removed c•••@mutuaterrassa.cat · •••5050
  • North Texas Infectious Disease Consultants, P.A. · Dallas, United StatesContact removed j•••@ntidc.org · •••2533
  • GI Alliance · Cedar Park, United StatesContact removed A•••@gialliance.com · •••0900
across 3 updates, Oct 30, 2026 – Nov 9, 2026
Show all 4 updates
  1. Nov 9, 2026
    GI Alliance is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • GI Alliance · Cedar Park, United StatesContact removed A•••@gialliance.com · •••0900
  2. Nov 2, 2026
    North Texas Infectious Disease Consultants, P.A. is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • North Texas Infectious Disease Consultants, P.A. · Dallas, United StatesContact removed j•••@ntidc.org · •••2533
  3. Oct 30, 2026
    2 sites added, 2 sites removed. 23 sites changed recruiting status (23 now active, not recruiting)
    Show 23 sites
    • New York Presbyterian Hospital · New York, United StatesRecruiting→Active, not recruiting
    • Medical University of South Carolina · Charleston, United StatesRecruiting→Active, not recruiting
    • Virginia Mason Medical Center · Seattle, United StatesRecruiting→Active, not recruiting
    • CCIH - Consultoria em Controle de Infecção Hospitalar Ltda · Belo Horizonte, BrazilRecruiting→Active, not recruiting
    • Fundacao Universidade de Caxias do Sul - Hospital Geral de Caxias do Sul · Caxias do Sul, BrazilRecruiting→Active, not recruiting
    • Associação Educadora São Carlos AESC - Hospital Mãe de Deus - Centro de Pesquisa · Porto Alegre, BrazilRecruiting→Active, not recruiting
    • Multiprofile Hospital for Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD · Gorna Oryahovitsa, BulgariaRecruiting→Active, not recruiting
    • Hospital St. Joseph · Les Paris, FranceRecruiting→Active, not recruiting
    • CHU Bordeaux - Hopital Saint Andre Service de medecine interne et maladies infectieuses · Bordeaux Cedex, FranceRecruiting→Active, not recruiting
    • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Paris Ile-de-France Ouest - Raymond-Poincare · Garches, FranceRecruiting→Active, not recruiting
    • Komárom-Esztergom Vármegyei Szent Borbála Kórház · Tatabánya, HungaryRecruiting→Active, not recruiting
    • Semmelweis Egyetem · Budapest, HungaryRecruiting→Active, not recruiting
    • Rabin Medical Center - Beilinson Hospital · Petah Tikva, IsraelRecruiting→Active, not recruiting
    • Carmel Medical Center · Haifa, IsraelRecruiting→Active, not recruiting
    • Hillel Yaffe MC, Clinical Research Unit · Hadera, IsraelRecruiting→Active, not recruiting
    • Ospedale Fatebenefratelli e Oftalmico, ASST Fatebenefratelli Sacco · Milan, ItalyRecruiting→Active, not recruiting
    • Fondazione IRCCS San Gerardo dei Tintori · Monza, ItalyRecruiting→Active, not recruiting
    • Osp. Pediatrico Bambino Gesù, IRCCS · Roma, ItalyRecruiting→Active, not recruiting
    • Presidio Ospedaliero di Vittorio Veneto · Vittorio Veneto, ItalyRecruiting→Active, not recruiting
    • FAICIC S de RL de C.V. - Gastroenterology · Veracruz, MexicoRecruiting→Active, not recruiting
    • Spitalul Clinic de Boli Infectioase Cluj-Napoca · Cluj-Napoca, RomaniaRecruiting→Active, not recruiting
    • Yonsei University, Wonju Severance Christian Hospital · Wŏnju, South KoreaRecruiting→Active, not recruiting
    • Hospital Universitario Mutua de Terrassa · Terrassa, SpainRecruiting→Active, not recruiting
    Show 2 added (2 Israel)
    • Shamir Medical Center (Assaf Harofeh) · Tsrifin, Israel
    • The Chaim Sheba Medical Center · Tel HaShomer, Israel
    Show 2 removed
    • Shamir Medical Center (Assaf Harofeh) · Ẕerifin, Israel
    • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
    Contact Study contact changed: C•••@vedantabio.com · •••1427→C•••@vedantabio.com · •••1427. See the current contact
    Site contacts Changed at 23 sites. See the sites
    Show 23 sites
    • New York Presbyterian Hospital · New York, United StatesContact removed t•••@med.cornell.edu · •••4463
    • Medical University of South Carolina · Charleston, United StatesContact removed h•••@musc.edu · •••4100
    • Virginia Mason Medical Center · Seattle, United StatesContact removed e•••@commonspirit.org · •••1416
    • CCIH - Consultoria em Controle de Infecção Hospitalar Ltda · Belo Horizonte, BrazilContact removed d•••@freirepesquisa.com.br · •••0085
    • Fundacao Universidade de Caxias do Sul - Hospital Geral de Caxias do Sul · Caxias do Sul, BrazilContact removed r•••@ucs.br · •••7200
    • Associação Educadora São Carlos AESC - Hospital Mãe de Deus - Centro de Pesquisa · Porto Alegre, BrazilContact removed g•••@coracentro.com.br · •••3930
    • Multiprofile Hospital for Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD · Gorna Oryahovitsa, BulgariaContact removed g•••@mcmedicaplus.com · •••6101
    • Hospital St. Joseph · Les Paris, FranceContact removed s•••@ghpsj.fr · •••6207
    • CHU Bordeaux - Hopital Saint Andre Service de medecine interne et maladies infectieuses · Bordeaux Cedex, FranceContact removed j•••@chu-bordeaux.fr · •••2433
    • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Paris Ile-de-France Ouest - Raymond-Poincare · Garches, FranceContact removed c•••@aphp.fr · •••5655
    • Komárom-Esztergom Vármegyei Szent Borbála Kórház · Tatabánya, HungaryContact removed h•••@tatabanyakorhaz.hu · •••9431
    • Semmelweis Egyetem · Budapest, HungaryContact removed k•••@semmelweis.hu · •••2783
    • Rabin Medical Center - Beilinson Hospital · Petah Tikva, IsraelContact removed m•••@clalit.org.il · •••5417Contact removed V•••@clalit.org.il · •••3570
    • Carmel Medical Center · Haifa, IsraelContact removed m•••@clalit.org.il · •••8822
    • Hillel Yaffe MC, Clinical Research Unit · Hadera, IsraelContact removed j•••@hymc.gov.il · •••4929Contact removed l•••@hymc.gov.il · •••2396
    • Ospedale Fatebenefratelli e Oftalmico, ASST Fatebenefratelli Sacco · Milan, ItalyContact removed p•••@asst-fbf-sacco.it · •••2582
    • Fondazione IRCCS San Gerardo dei Tintori · Monza, ItalyContact removed s•••@gmail.com · •••9600
    • Osp. Pediatrico Bambino Gesù, IRCCS · Roma, ItalyContact removed g•••@opbg.net · •••2188
    • Presidio Ospedaliero di Vittorio Veneto · Vittorio Veneto, ItalyContact removed a•••@email.it · •••5337
    • FAICIC S de RL de C.V. - Gastroenterology · Veracruz, MexicoContact removed a•••@faicic.com.mx · •••9780
    • Spitalul Clinic de Boli Infectioase Cluj-Napoca · Cluj-Napoca, RomaniaContact removed a•••@yahoo.com · •••1470
    • Yonsei University, Wonju Severance Christian Hospital · Wŏnju, South KoreaContact removed h•••@hanmail.net · •••1209
    • Hospital Universitario Mutua de Terrassa · Terrassa, SpainContact removed c•••@mutuaterrassa.cat · •••5050
  4. Sep 29, 2026
    Hadassah Medical Centre is now Withdrawn

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06237452
Lead sponsor
Vedanta Biosciences, Inc.
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
May 20, 2024
Primary completion
Jun 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Paul McGovern, MD
Contact
Consortium02-ctinquiries@vedantabio.com
857-706-1427
Steven Shiff, MD
Contact
Consortium02-ctinquiries@vedantabio.com
857-706-1427

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clostridia Strain Formulation VE303

Other studies in this condition

Clostridium Infections →

Other studies from this sponsor

Vedanta Biosciences, Inc.

Start the discussion